Impilo
Impilo AB, established in 2017, is a Stockholm-based private equity firm with an additional office in Copenhagen, Denmark. It specializes in buyout and growth capital investments in the healthcare sector, focusing on pharmaceuticals, medical technology, medical devices, care services, and preventative care segments. Impilo primarily targets unlisted companies in the Nordic region with revenues between SEK 200 million and SEK 1.5 billion, investing between SEK 100 million and SEK 1 billion. The firm prefers majority stakes but can also take minority positions, and it considers both public and private investments if a controlling position is available. Impilo's investment strategy aims to contribute positively to the communities and markets in which its portfolio companies operate, fostering long-term success.
Top Stages
7 past transactions
Qufora
Acquisition in 2024
Qufora is a medical device company that specializes in developing innovative solutions for individuals with chronic bowel disorders. The company focuses on designing and manufacturing urology care products, including medical irrigation solutions aimed at addressing bowel irrigation and dysfunction. Through its offerings, Qufora seeks to improve the quality of life for individuals dealing with chronic constipation and fecal incontinence, providing them with effective tools to manage their conditions.
Immedica
Private Equity Round in 2024
Immedica is a niche specialty pharmaceutical company focused on the commercialization and distribution of specialty pharmaceuticals, particularly in the areas of metabolic diseases, oncology, and ophthalmology. The company specializes in orphan medicines targeted at rare diseases, providing essential treatments that cater to specific medical needs. Through its efforts, Immedica aims to enhance access to niche drugs for clients, ensuring that patients with rare conditions receive the therapies they require.
VaccinDirekt
Acquisition in 2023
VaccinDirekt operates a network of vaccination clinics throughout Sweden, offering a range of medical services focused on vaccinations and travel medicine. The company provides health checks, issues medical and health certificates, and delivers expert advice and consultation for both infants and adults. VaccinDirekt ensures clients receive up-to-date information and support regarding their health needs. Communication with the company is facilitated through mail, phone, and in-person visits to its clinics.
Pelago Bioscience
Venture Round in 2023
Pelago Bioscience specializes in drug discovery through its proprietary Cellular Thermal Shift Assay technology. This innovative approach facilitates target engagement studies, allowing for the evaluation of drug candidate interactions with target proteins in various cellular and tissue environments. By providing more relevant data for drug delivery, Pelago's technology enhances the filtering of compounds based on physiologically relevant criteria. This leads to improved translation from laboratory research to patient applications, ultimately accelerating the development of new and more effective pharmaceuticals.
Decon
Acquisition in 2023
Decon is a manufacturer and supplier of medical equipment as well as accessories for all types of wheelchairs in the market.
Scantox
Acquisition in 2021
Scantox is a contract research organization located in Lille Skensved, Denmark, specializing in pharmacology and regulatory toxicology services. The company provides preclinical research services tailored for the pharmaceutical and medical device industries, assisting clients in advancing their drug or device development with reliable data that meets technical and scientific standards. Scantox offers a range of services, including safety pharmacology, exploratory testing, and endotoxin testing, ensuring comprehensive support throughout the product development process.
Cavidi
Venture Round in 2018
Cavidi AB, founded in 1984 as a spin-off from Uppsala University, is a Swedish biotech company specializing in viral load solutions for HIV monitoring. The company offers ZIVA Viral Load and ExaVIR Load systems for efficient management of anti-HIV drugs (ARV therapy), enabling people living with HIV to maintain a normal lifespan. These diagnostics also help reduce treatment costs and the spread of HIV. Cavidi provides research products and services, including reverse transcriptase activity kits and viral titer measurement services, to hospitals, patient clinics, private laboratories, pharmaceutical industries, and research institutions globally. The company's head office is in Uppsala, Sweden, with additional sales offices in South Africa, India, and the United States.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.